Seegene unveils ‘$12 PCR testing’ initiative to help end COVID-19 pandemic

Includes asymptomatic testing at community-based facilities to prevent widespread transmissions Regular testing for COVID-19, flu, RSV crucial for staying safe as anti-virus restrictions are eased ...

Seegene reports first quarter 2022 financial results

ㆍ Q1 revenue up 10% QoQ to reach record quarterly high of KRW 451.5 billionㆍ Foundation for sales expansion strengthened through ‘3 Ct’ technology commercialization, Allplex™ RV Master Assay approval,...

Seegene unveils world’s first commercialized ‘3 Ct’ PCR assay

 ㆍProvides Ct value of three targets in one channel; ‘3 Ct’ PCR assay to launch in H1 ㆍ“Dream MDx technology” developed based on Seegene’s 20-year expertise; combines 19 different patent tec...

Seegene’s Allplex™ RV Master Assay receives Australian TGA approval, European CE mark

South Korea’s leading molecular diagnostics (MDx) company, today announced that its Allplex™ RV Master Assay has received approval from Australia’s Therapeutic Goods Administration and achieved the Eu...

Seegene appoints Dr. Glen Hansen as Head of Medical Affairs of U.S. subsidiary

Dr. Hansen to provide clinical input to product development process; strengthen strategic partnerships with U.S. networksSecond leadership announcement for U.S. subsidiary in a monthSouth Korea’s lead...

Seegene appoints Richard Creager as CEO of U.S. subsidiary to bolster U.S. business

Dr. Creager to lead U.S. business from R&D, local production to M&A“Thrilled to create synergy to help Seegene grow as a top global molecular diagnostics company through success in U.S.”South Korea’s ...

Seegene unveils new assay optimized for on-site testing in ‘living with Covid-19’ era

Test can deliver results within 30 minutes, boosting testing capacity up to 5-foldOptimal for on-site testing at large-scale facilities such as schools, airportsAccuracy near to RT-PCR tests even for ...

Seegene Announces Q4 and Full-Year 2021 Financial Results

Seegene Signs Supply Deal to Deliver 4 million COVID-19 Tests to Brazil

- Seegene to sign a contract with the Brazilian government to supply 4 million COVID-19 tests and associated consumables- ‘Allplex™ SARS-CoV-2/FluA/FluB/RSV,’ the optimized test for ‘twindemic’ with i...

Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

- Scheduled to launch in late January, Seegene’s new COVID-19 test supports swift, large-scale lab testing with the same degree of accuracy as the conventional PCR testSeegene Inc. (KQ 096530), Sout...

Seegene’s Allplex™ SARS CoV-2 FluA/FluB/RSV Assay approved under Health Canada’s Interim Order

- Seegene’s syndromic assay detects COVID-19 and Influenza A/B/RSV infections in a single test.Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, announced it has received...

Seegene Continues to Support Israel’s Effort to Manage the Omicron Variant With Timely Delivery of Five Million Tests

- Seegene to export COVID-19 test that detects COVID-19 and Omicron along with its Master Assay that distinguishes between COVID-19 and other respiratory viruses Seegene Inc. (KQ 096530), South...

Seegene Unveils Blueprint for the Future of Molecular Diagnostics, Including Open Development Platform at the 40th Annual J.P. Morgan Healthcare Conference

Seegene Inc. (KQ 096530), South Korea’s leading molecular diagnostics (MDx) company, today, unveiled its blueprint for the future during a presentation at the 40th annual J.P. Morgan Healthcare vir...

Seegene Airlifts 1.7 million COVID-19 Tests to Israel Battling the Omicron Variant by a charter plane

- On December 29, Seegene to deliver Allplex™ SARS-CoV-2 Master Assay that can preemptively detect the Omicron variant at the primary screening stage- Earlier this month, the company has hired a pr...